Seminars in Hematology
Volume 41, Issue 3 , Pages 234-245 , July 2004

Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia

  • Jeanette Lundin

      Affiliations

    • Departments of Hematology/Oncology, Karolinska University Hospital, Stockholm, Sweden
    • Corresponding Author InformationAddress correspondence to Jeanette Lundin, MD, PhD, Department of Oncology, Karolinska Hospital, SE-171 76 Stockholm, Sweden
    • ,
  • Anders Österborg

      Affiliations

    • Departments of Hematology/Oncology, Karolinska University Hospital, Stockholm, Sweden

References 

  1. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517–522
  2. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, et al.  Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood. 1989;73:651–661
  3. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, et al.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J. 1993;293:633–640
  4. Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem. 1995;270:6088–6099
  5. Elsner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood. 1996;88:4684–4693
  6. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, et al.  Removal of T cells from bone marrow for transplantation (A monoclonal antilymphocyte antibody that fixes human complement). Blood. 1983;62:873–882
  7. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin’s lymphomas. J Clin Pathol. 1994;47:313–317
  8. Osterborg A, Werner A, Halapi E, Lundin J, Harmenberg U, Wigzell H, et al.  Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol. 1997;58:5–13
  9. Rawstron AC, Rollinson SJ, Richards S, Short MA, English A, Morgan GJ, et al.  The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment. Br J Haematol. 1999;107:148–153
  10. Lundin J, Porwit McDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, et al.  Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia. 2004;18:484–490
  11. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-cell antigen expression (Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies). Hematol J. 2001;2:300–306
  12. Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, et al.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726
  13. Tuset E, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma. 2001;42:1379–1383
  14. Birhiray RE, Shaw G, Guldan S, Rudolf D, Delmastro D, Santabarbara P, et al.  Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia. 2002;16:861–864
  15. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al.  Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol. 2003;123:850–857
  16. Xia MQ, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol. 1993;30:1089–1096
  17. Hale G, Rye PD, Warford A, Lauder I, Brito-Babapulle A. The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol. 1993;23:189–205
  18. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988;332:323–327
  19. Hale G, Dyer M, Clark M, Phillips J, Marcus R, Riechmann L, et al.  Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet. 1988;2:1394–1399
  20. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al.  CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas (A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma). J Clin Oncol. 1998;16:3257–3263
  21. Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567–1574
  22. de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, et al.  Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin’s lymphoma B cells in Scid mice. Exp Hematol. 1996;24:919–926
  23. Keating MJ, Flinn I, Jain V, Binet J-L, Hillmen P, Byrd J, et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine (Results of a large international study). Blood. 2002;99:3554–3561
  24. Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al.  Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891–3897
  25. Lozanski G, Heerema N, Flinn I, Smith L, Harbison J, Webb J, et al.  Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278–3281
  26. Elter T, Borchmann M, Reiser H, Schultz P, Staib T, Schinkoethe T, et al.  Development of a new four weekly schedule (FluCam) with concomitant application of campath-1H and fludarabine in patients with relapsed/refractory CLL. Proc Am Soc Clin Oncol. 2003;22:580; (abstr)
  27. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, et al.  Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245–2247
  28. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol. 1997;96:617–619
  29. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151–153
  30. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768–773
  31. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994;343:1177–1183
  32. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al.  Monoclonal antibody therapy for resected Dukes’ C colorectal cancer (Seven-year outcome of a multicenter randomized trial). J Clin Oncol. 1998;16:1788–1794
  33. O’Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, et al.  Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657–2663
  34. Wendtner C, Ritgen M, Fingerle-Rowson G, Jaeger G, Campe H, Engert A, et al.  High efficacy but considerable toxicity of campath-1H consolidation therapy in CLL patients responding to fludarabine—Results of a randomized phase III trial. Proc am Soc Clin Oncol. 2003;22:579; (abstr)
  35. Rai K, Byrd J, Peterson B, Larson R. A phase II trial on fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease (Cancer and Leukemia Group B (CALGB) study 19901). Blood. 2002;100(suppl):205a; (abstr)
  36. Montillo M, Cafro AM, Tedeschi A, Brando B, Oreste P, Veronese S, et al.  Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002;87:695–700
  37. Dyer MJ, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, et al.  In vivo “purging” of residual disease in CLL with Campath-1H. Br J Haematol. 1997;97:669–672
  38. DelleKarth G, Laczika K, Scholten C, Lechner K, Jaeger U, Schwarzinger I, et al.  Clearance of PCR-detectable lymphoma cells from the peripheral blood, but not bone marrow after therapy with campath-1H. Am J Hematol. 1995;50:146–147
  39. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82:807–812
  40. Kennedy B, Rawstron A, Evans P, English A, Haynes A, Russell N, et al.  Campath-1H therapy in 29 patients with refractory CLL (“True complete remission is an attainable goal.”). Blood. 1999;94(suppl):603a; (abstr)
  41. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C, et al.  Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78:3269–3274
  42. Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, et al.  Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15:2667–2672
  43. Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, et al.  Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20:205–213
  44. Skotnicki AB, Robak T, Mayer J, Craig A, Weitman S. Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM 307). Blood. 2003;102(suppl):439a; (abstr)
  45. Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al.  Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267–4272
  46. Brett S, Baxter G, Cooper H, Johnston JM, Tite J, Rapson N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology. 1996;88:13–19
  47. Hertenstein B, Wagner B, Bunjes D, Duncker C, Raghavachar A, Arnold R, et al.  Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86:1487–1492
  48. Rezvany MR, Lundin J, Edman P, Porwit McDonald A, Mellstedt H, Österborg A. Long-term follow-up of lymphocyte subsets after subcutaneous alemtuzumab treatment as primary therapy for B-CLL. Blood. 2002;100(suppl):207a; (abstr)
  49. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al.  Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354:1691–1695
  50. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma (Implications for clinical trials in this patient population). Cancer. 2002;94:2033–2039
  51. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA. 1988;85:208–212
  52. Tedder TF, Zhou LJ, Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol Today. 1994;15:437–442
  53. O’Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics. 1998;48:125–132
  54. Manshouri T, Do KA, Wang X, Giles FJ, O’Brien SM, Saffer H, et al.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101:2507–2513
  55. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–3947
  56. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol. 2003;30:424–433
  57. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma (Half of patients respond to a four-dose treatment program). J Clin Oncol. 1998;16:2825–2833
  58. Berinstein N, Grillo-Lopez A, White CA, Bence-Brudiler I, Maloney D, Czuczman M, et al.  Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:1–7
  59. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317–324
  60. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al.  Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326–1331
  61. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders (Evaluation of response on 48 patients). Eur J Haematol. 1999;62:76–82
  62. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217–2224
  63. Itälä M, Geisler C, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, et al.  Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia (Results from a Nordic multicentre study). Eur J Haematol. 2002;69:129–134
  64. Faderl S, Thomas DA, O’Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, et al.  Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413–3415
  65. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–2164
  66. O’Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–2170
  67. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia (Results from Cancer and Leukemia Group B9712 (CALGB9712)). Blood. 2003;100:6–14
  68. Wierda W, O’Brien S, Albitar M, Lerner S, Pulunkett W, Giles FJ, et al.  Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood. 2001;98(suppl):771a; (abstr)
  69. Jensen M, Winkler U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol. 1998;77:89–91
  70. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al.  Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells (Association with increased infusion-related side effects and rapid blood tumor clearance). J Clin Oncol. 1999;17:791–795
  71. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro (Synergistic direct antiproliferative and apoptotic effects). Blood. 2002;100:1765–1773
  72. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al.  Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21:3051–3059
  73. Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, et al.  Epratuzumab, a humanized monoclonal antibody targeting CD22 (Characterization of in vitro properties). Clin Cancer Res. 2003;9(suppl):3982S–3990S
  74. Emmanouilides C, Leonard J, Schuster S, Couture F, Mills A, Koutsoukos A, et al.  Multi-center, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood. 2003;102(suppl):69a; abstr
  75. Gingrich R, Dahle C, Hoskins K, Senneff M. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood. 1990;75:2375–2387
  76. Mone A, Lucas D, Aron J, Cheney C, Johnson A, Bains S. Hu1D10 induced parallel death and survival signals in chronic lymphocytic leukemia (CLL) cells (Justifications for combination studies of Hu1D10 with P13 kinase inhibitors). Blood. 2002;100(suppl):386a; (abstr)
  77. Link B, Wang H, Byrd J, Leonard J, Davis T, Flinn I, et al.  Phase I study of Hu1D10 monoclonal antibody in patients with B-cell lymphoma. Proc Am Soc Clin Oncol. 2001;20:284a; (abstr)
  78. Hedge U, White T, Stetler-Stevenson M, Marti GE, Janik J, Pittaluga S, et al.  Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia. Blood. 2002;100(suppl):358a; (abstr)
  79. Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol. 1984;2:881–891
  80. Dillman RO, Beauregard J, Shawler DL, Halpern S, Markman M, Ryan K, et al.  Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Response Mod. 1986;5:394–410
  81. Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, et al.  Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood. 1984;64:1085–1093
  82. Schroff RW, Farrell MM, Klein RA, Oldham RK, Foon KA. T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients. J Immunol. 1984;133:1641–1648
  83. Pathan N, Hariharan K, Hopkins M, Saren A, Rett M, Hanna N, et al.  Induction of apoptosis by IDEC-152 (anti-CD23) in lymphoma cells. Blood. 2001;98(suppl):367a; (abstr)
  84. Byrd J, O’Brien S, Flinn I, Kipps T, Weiss M, Reid J, et al.  Interim results from a phase I study of lumiliximab (IDEC-152, anti-CD23, antibody) therapy for relapsed or refractory CLL. Blood. 2003;102(suppl):74a; (abstr)
  85. William F, Snider C, Strom T, Murphy J. Structure/function analysis of interleukin-2-toxin (DAB486IL-2) (Fragment B sequences required for the delivery of fragment A to the cytosol of target cells). J Biol Chem. 1990;265:118–185
  86. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376–388
  87. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma (Decreased frequency and severity with steroid premedication). Clin Lymphoma. 2001;1:298–302
  88. Seymour JF, Morgan S, Wolf M, Prince HM, Westerman D. Denileukin diftitox (Ontac), an interleukin-2 (IL-2) fusion toxin has significant activity in fludarabine-refractory chronic lymphocytic leukemia (CLL). Blood. 2003;102(suppl):673a; (abstr)
  89. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol. 2000;27:62–73
  90. Kaminski MS, Zelenetz AD, Press O, Saleh M, Leonard L, Fehrenbacher L. Multicenter phase III study of iodine-131-tositumomab (anti-B1 antibody) for chemotherapy-refractory low grade or transformed low grade non-Hodgkin’s lymphoma. Blood. 1998;92(suppl):316a; (abstr)
  91. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, et al.  Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991;51:4052–4058
  92. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241–247
  93. Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin’s lymphoma. Clin Cancer Res. 2002;8:836–845
  94. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–5144
  95. Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res. 2000;24:411–415
  96. Flinn I, Sickler J, Lucas M, Buj V, Waymer S, Shinn C, et al.  Randomized trial of early versus delayed GM-CSF with Campath-1H (Preliminary feasibility and correlative biologic studies results). Blood. 2000;96(suppl):838a; (abstr)
  97. Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, et al.  Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica. 2003;88:1002–1012
  98. Pangalis GA, Dimopoulou MN, Angelopoulou MK, Tsekouras C, Vassilakopoulos TP, Vaiopoulos G, et al.  Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol. 2001;18:99–107
  99. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al.  Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma (Safety and efficacy of re-treatment). J Clin Oncol. 2000;18:3135–3143

☆ Supported in part by the Swedish Cancer Society, the Cancer Society in Stockholm, and the Karolinska Institutet Foundations.

PII: S0037-1963(04)00092-7

doi: 10.1053/j.seminhematol.2004.05.005

Seminars in Hematology
Volume 41, Issue 3 , Pages 234-245 , July 2004

Article Tools